Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piu Medical SpAMIL:PMED -1.75%14 Debt-to-EBITDA is 4.50 as of Jun. 2025, which is 48% above its 10-year median of 3.05. GuruFocus rates MIL:PMED with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Piu Medical SpA ranks worse than 97.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Piu Medical SpA's Debt-to-EBITDA or its related term are showing as below:
MIL:PMED'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.98 Med: 3.05 Max: 40.78
Current: 24.72
During the past 3 years, the highest Debt-to-EBITDA Ratio of Piu Medical SpA was 40.78. The lowest was 2.98. And the median was 3.05.
MIL:PMED's Debt-to-EBITDA is ranked worse than 97.07% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs MIL:PMED: 24.72
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Piu Medical SpA Debt-to-EBITDA Related Terms
Piu Medical SpA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Piu Medical SpA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piu Medical SpA Debt-to-EBITDA Chart
Piu Medical SpA Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
3.05
2.98
40.78
Piu Medical SpA Semi-Annual Data
Dec23
Dec24
Jun25
Dec25
Debt-to-EBITDA
N/A
N/A
4.50
-14.72
Piu Medical SpA Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Piu Medical SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piu Medical SpA Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Piu Medical SpA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Piu Medical SpA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
Piu Medical SpA (MIL:PMED) has a Debt-to-EBITDA of 4.50 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Piu Medical SpA. This is 48% above median its historical median of 3.05. Over the past decade, Piu Medical SpA's Debt-to-EBITDA has ranged from 2.98 to 40.78. According to the industry distribution chart, Piu Medical SpA ranks #464 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 97.1%.
Is Piu Medical SpA's Debt-to-EBITDA too high?
Piu Medical SpA's current Debt-to-EBITDA of 4.50 is 48% above median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 2.98 to a high of 40.78. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Piu Medical SpA's value of 4.50 is 105% above this industry median. Based on the distribution chart, Piu Medical SpA ranks #464 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Piu Medical SpA has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Piu Medical SpA's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Piu Medical SpA ranks #464 out of 478 companies for Debt-to-EBITDA. This places Piu Medical SpA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Piu Medical SpA's value of 4.50 is 105% above this benchmark. Historically, Piu Medical SpA's own Debt-to-EBITDA has ranged from 2.98 to 40.78 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 2.20, Piu Medical SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piu Medical SpA's current Debt-to-EBITDA of 4.50 is 105% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Piu Medical SpA. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piu Medical SpA's current Debt-to-EBITDA is 4.50, which is 48% above median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piu Medical SpA stock overvalued right now?
Piu Medical SpA (MIL:PMED) has a current Debt-to-EBITDA of 4.50. The current Debt-to-EBITDA is 4.50, which is 48% above median its 10-year median of 3.05 and 105% above the Healthcare Providers & Services industry median of 2.20. Piu Medical SpA's overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Piu Medical SpA (MIL:PMED), the current Debt-to-EBITDA is 4.50 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Piu Medical SpA specializes in the retail distribution of pharmaceutical and parapharmaceutical products. Its activity includes: sale of prescription drugs; sale of OTC and parapharmaceutical products: OTC medicines, dietary supplements, medical devices, paramedical products, personal care and wellness products, homeopathic medicines, cosmetics, etc.; services: diagnostic testing services, blood parameter analysis and control (glycemia, cholesterol, triglycerides, etc.), rapid testing and screening, nutritional consultation, remote medical assistance and monitoring, telemedicine, etc.
14GF Score
Get the complete analysis for MIL:PMED
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PMED has been successfully added to your 
